NCT06640010

Using Induced-Pluripotent Stem Cells to Model Cancer Therapy-Related Adverse Events

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 30 (estimated)
• Sponsor: Mayo Clinic · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is being done to find out if patient blood samples can be used to perform individualized modeling of cancer therapy-related side effects.

Detailed description

PRIMARY OBJECTIVES: I. Generate induced pluripotent stem cells (iPSC's) from patients receiving cancer treatment. II. Differentiate patient iPSC's into cardiomyocytes and/or neurons or other cell types that may be relevant to modeling cancer therapy-related adverse effects, such as cardiotoxicity and neurotoxicity. III. Use patient specific iPSC-derived cells to: IIIa. Model cancer therapy-related toxicities; IIIb. Better understand the mechanisms of toxicities; IIIc. Determine if patient specific genetic variants are causative of toxicities; IIId. Screen novel protective therapies for cancer therapy-related toxicities. OUTLINE: This is an observational study. Patients undergo blood sample collection and have their medical records reviewed on study.

Conditions

• Hematopoietic and Lymphatic System Neoplasm
• Malignant Solid Neoplasm

Interventions

Type	Name	Description
OTHER	Non-Interventional Study	Non-interventional study

Timeline

• Start date: 2025-01-13
• Primary completion: 2026-12-15
• Completion: 2026-12-15
• First posted: 2024-10-15
• Last updated: 2026-01-06

Locations

1 site across 1 country: United States